• Platinum Level Sponsor:
  • Gold Level Sponsor:
  • Silver Level Sponsor:
  • Silver Level Sponsor:
  • Bronze Level Sponsor:
  • Bronze Level Sponsor:
  • Travel Grants are sponsored by:
Home / Abstracts / Call for Abstracts

Call for Abstracts

All participants are invited to submit abstracts for presentation at MipTec 2013

Abstract Submission has been closed.

GUIDELINES for submission of abstracts:

  1. Abstracts may be submitted only via Internet. Please make sure to state your correct E-mail address as well as your full name and company (for publishing purposes).
    Please use GB as abbreviation for United Kingdom.
  2. Abstracts submitted via fax or E-mail will not be accepted.
  3. All abstracts must be submitted and presented in English.
  4. Abstracts should contain original material neither published nor presented elsewhere prior to September 24, 2013.
  5. The abstract text may not be longer than 2500 characters, including spaces, excluding title and authors.
  6. Tables, charts and other graphics may be included in the abstract in gif or jpg format of high resolution and suitable for reproduction in black & white. A separate upload button is provided (max. 3 graphics per abstract of not more than 20kb in total).
  7. Avoid complex mathematical formulae. For the symbols ≤ or ≥, type instead <= or >= and for e.g. 106, type instead 10^6. Avoid Greek letters and symbols. Instead of ‘IFN-γ’ use for example ‘IFN-gamma’, etc.
  8. All abbreviations must be defined the first time they appear in your text (but, do not define in the title).
  9. Authors are requested to select a topic under which they wish their abstract to be reviewed.
  10. Select your preferred method of presentation: oral or poster.
    As the number of oral time slots is limited, the Program Committee may ask authors who prefer oral, to present their work as a poster.
  11. After having submitted your abstract, you will receive a confirmation by E-mail with the following information:

    • reference number of your abstract (for correspondence and questions that may arise)
    • your personal user code (E-mail address) and password.

    Should you wish to make corrections to an abstract already submitted or if you wish to submit other abstracts later, you may use your personal user code and password. Please note that alterations cannot be made after the above mentioned abstract deadlines.
    If you do not receive a confirmation by E-mail please contact the Abstract Hotline.
    A further E-mail “Your Dummy has been deleted” refers to a possible incomplete abstract submission. Incomplete abstracts will be deleted from our system after 24 hours.
    Please note that if you If you did receive a confirmation by E-mail indicating an abstract number, your abstract has been successfully registered in our database. No further steps are required.  

  12. Authors of abstracts will be notified of the via E-Mail of the acceptance by the beginning of August 2013.
  13. Acceptance of an abstract implies registration and attendance at the conference.

If you have difficulties in submitting your abstract or if you need any further information,
please contact the Abstract Hotline.

Phone: +41 61 686 77 22 (Monday – Friday during CET business hours)
E-mail: abstracts.ch@congrex.com

Topics for Abstract Submission:

  1. Medicinal Chemistry of Chemical Space
    John Harris, Anne Hersey and Chris Lipinski are the organizing co-chairs for the MIPTEC2013 morning and afternoon Chemical Space sessions on Tuesday September 24, 2013. The session will focus on the exploration of chemistry space from the perspectives of the ligand (drug) structure, the target structure and will include both computational and structural biology perspectives. We hope especially to emphasize efforts towards discovery of ligands for difficult targets such as protein-protein interactions and epigenetic targets. The presentations will be balanced between broad exploration of the topic and case studies. We anticipate that the talks by the nine speakers spanning academia and industry across the morning and afternoon Tuesday sessions will be of particular interest to chemical biologists, and medicinal chemists involved in drug discovery and to the disciplines working closely with these groups.

  2. Stem Cells in Biomedicine
    The Nobel Prize for Medicine 2012, jointly awarded to Sir John Gurdon and Professor Shinya Yamanaka, was an appropriate sign of recognition for their ground-breaking discoveries that mature cells can be reprogrammed to become pluripotent (iPSC; induced pluripotent stem cells). The capability to subsequently differentiate iPSCs to generate lineage specific cell types has far-reaching consequences. The implications for developmental biology and the potential applications in healthcare are immense. This session will address our current knowledge of stem cell biology, how pluripotent stem cells can be generated, characterized and in particular how knowledge of  stem cells can be used to advance our understanding of disease and therapies.

  3. Next Generation Sequencing
    Next generation DNA sequencing (NGS) platforms have accelerated clinical and research genomics because they provide an inexpensive and scalable way to interrogate genetic differences, gene expression, and other epigenetic and epitranscriptomic variations of DNA and RNA.  Also, high-throughput methods for proteomics and metabolomics are now being added as features for patients to examine during routine doctor’s visits.  As these tools mature, they are increasingly being utilized in clinical applications for disease stratification, patient personalization of treatment regimens, and longitudinal molecular monitoring of genotype-phenotype changes.  In this symposium, we will focus on recent technological, computational, and clinical approaches in leveraging these integrative genomics methods for advancing personalized and precision medicine.

  4. High Content Screening
    High-content screening has become an established technology in drug discovery and in basic research. Advances in the application of high-content screening to more complex and more diverse biological models have been accompanied by the development of an expanding repertoire of increasingly more sophisticated image analysis and statistical data analysis methods. Such advances have stimulated increased adoption of high-content screening strategies and together with novel solutions for data management ensure that high-content screening is a dynamic and rapidly evolving field driving innovations across drug discovery and basic science. In the presentations of the morning session we will cover many of the latest developments in various aspects of high-content screening from new biology models to image and data analysis as well as data management and the challenges and opportunities presented by emerging phenotypic screening strategies. The afternoon session will be in an interactive format, with discussion topics driven by the participants’ input, aimed at both novice and experienced HCS users. Like in the past years, we will exchange ideas, discuss urgent needs, and (try to) solve real-world problems.

  5. Peptide Therapeutics
    Description: Two sessions, “Peptide Discovery” and “Development of therapeutic Peptides”, are foreseen for the Peptide Therapeutics Forum. The first parts provides an introduction into the various methods of finding peptide leads including display selection of large libraries, screening of particular natural product collections, and the design of cyclic peptides. The afternoon session is dedicated to more advanced peptide drugs including the field of type II diabetes, oncology and issues related to delivery. This event on peptides is thought to disseminate information on latest developments in the field of therapeutic peptides and to enable networking of interested parties from academia and industries.

  6. Impact of Enzymology on Drug Discovery
    In modern drug discovery, the integration of activity data from high-throughput assays, binding data from biophysical methods as well as structural information has opened new perspectives in the field of Enzymology. In addition to established parameters such as IC50 and KD values, there is now an increasing interest in guiding the development of structure activity relationships by means of binding kinetics and thermodynamics. However, at the same time, there needs to be a better understanding of how all of these parameters fit in with the increasing complexity of target biology. The Enzymology forum will cover topics on how Enzymology can increase the predictability of biochemical assays, particularly for challenging targets (e.g., reconstitution of membrane proteins or multi-protein complexes), and analytical concepts that translate assay data into mechanistic understanding of the interaction of drug molecules with their targets (e.g., tight binding and drug-target residence time).

  7. Developing Drugs for and with Patients: Biobanking 3.0, Biomarkers and Customized Therapies
    Developing Drugs for and with Patients: Biobanking 3.0, Biomarkers, and Customized Therapies The causes of disease, as well as the actions of drugs, vary between patients. Recognizing this means re-focusing biomedical R&D on the individual. In the biomolecular research lab, patients are represented by specimens, annotated with clinical data. To develop successful drugs, we must raise the quality of specimens, combine them with more meaningful data, and identify more relevant biomarkers. Meanwhile, patients increasingly claim their right to be involved in the process. This is a challenge, but even more so, a chance to be embraced.Our forum aims to represent the current state of the science to translate clinical findings into promising research hypotheses, and biomedical research results into successful clinical outcomes. Leaders in their field will identify challenges and chances, foster debate, and report on solutions.

  8. Natural Products and Synthetic Biology
    Natural Products and Synthetic biology are two areas of research that are finding increasing areas of overlap. Genetic engineering has been applied to natural products research almost since its inception in the early 1970’s, however, genetic engineering itself is undergoing a revolution catalyzed by the widespread application of next generation sequencing technologies, improvements in DNA synthesis technologies and from progress made in the rapidly developing field of synthetic biology. The goal of this session is to survey research from laboratories working at the nexus of these two fields with an emphasis placed on discovering how recent advances in the field of synthetic biology can help drive natural products research to facilitate drug discovery.

  9. Industry-Academic Collaboration
    This session will examine and discuss models for partnering between academic drug discovery groups and pharmaceutical companies. Both existing relationships and new mechanisms of interaction that have developed in today’s rapidly changing world will be examined. This session will include both presentations and a panel discussion where the audience’s topics will be welcomed.

  10. Jumpstarting Innovations

Notification of authors

Abstracts are subject to approval by the Program Committee and to final assignment for inclusion in the program as an oral or poster presentation. Authors will be notified by E-mail (therefore it is essential that you indicate your correct E-mail address) in the beginning of August 2013. Authors will be informed as to whether they are to present their abstract orally or in the form of a poster. Full instructions concerning the preparation and presentation will be included.


All accepted abstracts will be published.

Young Scientists Travel Grant

Young scientists interested in this travel grant should click the appropriate checkbox during the online abstract submission process. You will be required to upload a copy of your student identification as proof of eligibility. Prepare this document in one of the following formats: MS Word document, gif, jpg or pdf file.
If you have difficulties uploading your passport copy, please contact the Abstract Hotline on ++41 61 686 7722.

Abstract Submission has been closed.